# Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC

Source: [Biological sciences : nature.com subject feeds](https://www.nature.com/articles/s41698-026-01779-2) · 2026-11-19 · Life
Page: https://themorning.science/story/targeting-smyd3-in-cancer-associated-fibroblasts-relieves-immune-suppression-and-4d925f664a6c60c5
Kind: research · Impact: medium

## In brief

- A study reports that targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression in HPV-negative head and neck squamous cell carcinoma (HNSCC).
- The study reports that this approach improves response to anti-PD-L1 therapy in HPV-negative HNSCC.

## Why it matters

It suggests that targeting fibroblasts, rather than tumour cells alone, could make anti-PD-L1 immunotherapy more effective in HPV-negative head and neck cancer.

## Timeline

- 2026-11-19: Study published in npj Precision Oncology (nature.com feed)

## Coverage

- [Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC](https://www.nature.com/articles/s41698-026-01779-2) — Biological sciences : nature.com subject feeds, 2026-11-19

Tags: smyd3, hnscc, immunotherapy, pd-l1, cancer-associated-fibroblasts

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
